FY19 $1.25 target, page-39

If we keep these projections of masterblaster fixed:
Pelvic & Hernia revenues could be $28m
Medical product sales business I forecast at $11m.

and work off Stonemasons margins:
22% margin and 30 p/e

we can look at the following share price based on the CHD sales

36,000 = 39 cents
50,000 = 47 cents
75,000 = 63 cents
90,000 = 71 cents

I'm hoping, not predicting (Meerkat!), that we will be more around the 75,000 mark in 3 years.

Then we need to add on the value of the HPV and HSV2 treatments / vaccines.
I safely assume this will be worth $100 billion

so all is looking good!